| Dr Wesley H Chou, MD | |
|
201 Park St, Bowling Green, KY 42101-1759 | |
| (270) 781-5111 | |
| (270) 780-0494 |
| Full Name | Dr Wesley H Chou |
|---|---|
| Gender | Male |
| Speciality | Neurology |
| Experience | 46 Years |
| Location | 201 Park St, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841294717 | NPI | - | NPPES |
| 130025800 | Other | KY | RAILROAD MEDICARE |
| 000000248514 | Other | KY | ANTHEM |
| 64059603 | Medicaid | KY | |
| 50003106 | Other | KY | PASSPORT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 37553 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| The Medical Center At Franklin | Franklin, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gilbert Barbee Moore And Mcilvoy Psc | 4082511167 | 223 |
| Bowling Green Warren County Community Hospital Corporation | 7719899947 | 31 |
News Archive
The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.
North West London Pathology, hosted by Imperial College Healthcare NHS Trust, and Abbott announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
Science Applications International Corporation today announced it has been awarded a task order by the Walter Reed Army Medical Center Directorate of Information Management to provide information technology services.
› Verified 3 days ago
| Entity Name | Gilbert Barbee Moore & Mcilvoy Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114948288 PECOS PAC ID: 4082511167 Enrollment ID: O20031217000136 |
News Archive
The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.
North West London Pathology, hosted by Imperial College Healthcare NHS Trust, and Abbott announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
Science Applications International Corporation today announced it has been awarded a task order by the Walter Reed Army Medical Center Directorate of Information Management to provide information technology services.
› Verified 3 days ago
| Entity Name | Bowling Green Warren County Community Hospital Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942990767 PECOS PAC ID: 7719899947 Enrollment ID: O20230703000877 |
News Archive
The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.
North West London Pathology, hosted by Imperial College Healthcare NHS Trust, and Abbott announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
Science Applications International Corporation today announced it has been awarded a task order by the Walter Reed Army Medical Center Directorate of Information Management to provide information technology services.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Wesley H Chou, MD 201 Park St, Bowling Green, KY 42101-1759 Ph: (270) 781-5111 | Dr Wesley H Chou, MD 201 Park St, Bowling Green, KY 42101-1759 Ph: (270) 781-5111 |
News Archive
The new variant of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) detected in England replicates more than two times faster than the earlier strains. This replication advantage promises to make it the dominant global variant very shortly. This finding comes from a startling preprint that appeared on the medRxiv* server in December 2020.
North West London Pathology, hosted by Imperial College Healthcare NHS Trust, and Abbott announced today that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.
CMC Biologics and OncoSynergy have entered into an agreement for process development and GMP manufacture of OS2966 – a novel potential treatment for Ebola. The investigational drug candidate, designed to inhibit a major cellular adhesion receptor (CD29) that is fundamental for progression of aggressive and resistant cancer tumors, was granted orphan drug designation by the U.S. FDA earlier this year in the treatment of glioblastoma.
Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the second quarter and the first six months ended June 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.
Science Applications International Corporation today announced it has been awarded a task order by the Walter Reed Army Medical Center Directorate of Information Management to provide information technology services.
› Verified 3 days ago
Dr. David Tamayo, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 707 E Main St, Bowling Green, KY 42101 Phone: 270-901-5000 Fax: 270-842-6553 | |
Dr. Jose Elavath Paul, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 380 Suwannee Trail Street, Bowling Green, KY 42103 Phone: 270-901-5000 Fax: 270-842-6553 | |
Dr. Jianhua Zhu, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-780-0483 | |
Mrinal Mullick, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 350 Park St, Suite 204, Bowling Green, KY 42101 Phone: 270-843-5103 Fax: 270-843-5104 | |
Jae Eun Lee, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-783-3315 Fax: 270-783-3774 | |
Dr. Max Calvin Kinnaman Jr., D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 380 Suwannee Trail St, Bowling Green, KY 42103 Phone: 270-901-5000 Fax: 270-842-5268 | |
Norman Leeper, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1035 Porter Pike, Bowling Green, KY 42103 Phone: 270-843-1199 Fax: 270-782-9996 |